CA3024180A1 — Inhibitors of the menin-mll interaction
Assigned to Vitae Pharmaceuticals LLC · Expires 2017-12-14 · 8y expired
What this patent protects
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, such as a compound of Formula I:or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing the same, and their use in the treatment of cancer a…
USPTO Abstract
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, such as a compound of Formula I:or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction. The menin-MLL complex is implicated in MLL-related leukemia, and disrupting this interaction selectively inhibits leukemia cell growth. The disclosed compounds and methods offer a promising avenue for developing effective treatments targeting the menin-MLL interaction in diverse diseases such as leukemia, prostate cancer, and diabetes.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.